CRISPR19V

Sigma-Aldrich

Lenti CRISPR Universal Non-Target Control#2 Transduction Particles (LV04 vector)

NACRES:
NA.51

品質水準

200

包装

vial of 200 μL

濃度

(1x106 TU/mL (via p24 titering assay))

アプリケーション

CRISPR: suitable

出荷済み

dry ice

保管温度

−70°C

詳細

The Lenti CRISPR Non-Target Control#2 Transduction Particles (LV04 vector) include a gRNA sequence that does not target known human, mouse and rat genes. The non-target control#2 transduction particles are useful as a negative control in experiments using CRISPR lentiviral clones and for cell types that are not amenable to transfection. The Lenti CRISPR Non-Target Control#2 uses a dual-component system consisting of U6-driven guide RNA (non-target#2) and hPGK-driven Puromycin resistance cassette and Blue Fluorescence Protein for fluorophorescence. This control requires Cas9 be delivered by a separate vector.

Lentiviral-based particles permit efficient infection and integration of the construct into differentiated and non-dividing cells, such as neurons and dendritic cells, overcoming low transfection and integration difficulties when using these cell lines. Self-inactivating replication incompetent viral particles are produced in packaging cells (HEK293T) by co-transfection with compatible packaging and envelope plasmids.

アプリケーション

Functional Genomics/Screening/Target Validation

その他情報

Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells, respectively.

RIDADR

UN 3245 9

ドイツ水質汚染分類

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable

試験成績書(COA)
原産地証明書(COO)

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

テクニカルサービス連絡先

ソーシャルメディア

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

研究、開発、製造

私たちは、バイオテクノロジーと医薬品の研究&開発および製造のソリューションとサービスを提供する、グローバルなライフサイエンス業界のリーディングサプライヤーです。

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

当ウェブサイトのいかなる内容についても、許可なく複写することを禁じます。